v3.26.1
Liabilities related to business combinations and to non-controlling interests (Tables)
 6 Months Ended
Jun. 30, 2026
Disclosure of contingent liabilities in business combination [abstract]  
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests
Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown below:
(€ million)Shire contingent consideration arising from acquisition of Translate BioCVRs issued in connection with the acquisition of BlueprintCVRs issued in connection with the acquisition of VigilOther
Total (a)
Balance at January 1, 2026
531 48 5 1 585 
Payments made— — — — — 
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b)
38 8 3 — 49 
Currency translation differences16 2 1 (1)18 
Balance at June 30, 2026
585 58 9 — 652 
Of which:
•Current portion
— 
•Non-current portion
652 
(a)As of January 1, 2026, this comprised a non-current portion of €585 million.
(b)    Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.